IceCure Medical Extends Equity Distribution Agreement with Maxim Group to March 2026

An update from Icecure Medical ( (ICCM) ) is now available.

On January 8, 2026, IceCure Medical Ltd. signed a first amendment to its equity distribution agreement with Maxim Group LLC, extending the termination date of the arrangement from January 13, 2026, to March 13, 2026. The amendment preserves the company’s ability to offer and sell up to $13,960,500 of its ordinary shares through Maxim over this extended period, effectively giving IceCure additional flexibility and time to tap the at-the-market equity program as a financing tool within the existing $13.96 million capacity.

The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

Icecure Medical’s overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. The technical analysis indicates a bearish trend, and valuation metrics are weak due to unprofitability. However, the positive sentiment from the earnings call, driven by FDA approval and strategic market opportunities, provides some optimism for future growth.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical Ltd., based in Caesarea, Israel, is a foreign private issuer listed in the United States that operates in the medical technology sector and issues ordinary shares to support its business activities. The company utilizes equity distribution arrangements with investment banks, such as Maxim Group LLC, to access U.S. capital markets and raise funds as needed over time.

Average Trading Volume: 482,617

Technical Sentiment Signal: Sell

Current Market Cap: $47.09M

Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.